Copyright © 2001 American Medical Association. All rights reserved. From: Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary SyndromesThe MIRACL Study: A Randomized Controlled Trial JAMA. 2001;285(13):1711-1718. doi:10.1001/jama.285.13.1711 Figure Legend: Number of patients screened was not determined. Follow-up informationwas sought for all patients who were withdrawn early from the study (priorto the a priori cutoff of 100 days). Date of download: 10/19/2017 Copyright © 2001 American Medical Association. All rights reserved.

Copyright © 2001 American Medical Association. All rights reserved. From: Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary SyndromesThe MIRACL Study: A Randomized Controlled Trial JAMA. 2001;285(13):1711-1718. doi:10.1001/jama.285.13.1711 Figure Legend: Values are mean (95% confidence interval). To convert values forcholesterol to mmol/L, multiply by 0.0259; to convert values for triglyceridesto mmol/L, multiply by 0.0113. The differences between treatment groups (atorvastatinminus placebo) in adjusted mean percentage change from baseline at 6 weeksand at 16 weeks, respectively, were −37.5 and −34.0 (both P<.001) for total cholesterol; −55.9 and −52.0(both P<.001) for low-density lipoprotein cholesterol; −0.6(not significant) and 1.6 (P = .04) for high-densitylipoprotein cholesterol; and −27.5 and −25.0 (both P<.001) for triglycerides. Date of download: 10/19/2017 Copyright © 2001 American Medical Association. All rights reserved.

Copyright © 2001 American Medical Association. All rights reserved. From: Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary SyndromesThe MIRACL Study: A Randomized Controlled Trial JAMA. 2001;285(13):1711-1718. doi:10.1001/jama.285.13.1711 Figure Legend: The relative risk of the composite outcome in the atorvastatin groupcompared with the placebo group was 0.84 (95% confidence interval, 0.70-1.00; P = .048), based on a Cox proportional hazards analysis.The decrease in number at risk at 16 weeks reflects the fact that many patientscompleted the study within the days immediately preceding 16 weeks. Date of download: 10/19/2017 Copyright © 2001 American Medical Association. All rights reserved.

Copyright © 2001 American Medical Association. All rights reserved. From: Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary SyndromesThe MIRACL Study: A Randomized Controlled Trial JAMA. 2001;285(13):1711-1718. doi:10.1001/jama.285.13.1711 Figure Legend: Death, nonfatal acute myocardial infarction, and resuscitated cardiacarrest were not significantly reduced in the atorvastatin group compared withthe placebo group. Recurrent symptomatic myocardial ischemia with objectiveevidence and requiring urgent rehospitalization was significantly reducedin the atorvastatin group compared with the placebo group (relative risk,0.74; 95% confidence interval, 0.57-0.95). Date of download: 10/19/2017 Copyright © 2001 American Medical Association. All rights reserved.